Flat epithelial atypia and risk of breast cancer: A Mayo cohort study. Issue 10 (13th January 2015)

• Record Type: Journal Article
• Authors: Said, Samar M.; Visscher, Daniel W.; Nassar, Aziza; Frank, Ryan D.; Vierkant, Robert A.; Frost, Marlene H.; Ghosh, Karthik; Radisky, Derek C.; Hartmann, Lynn C.; Degnim, Amy C.
• Is Part Of: Cancer. Volume 121:Issue 10(2015)
• Page Start: 1548
• Page End: 1555
• Publication Date: 2015-01-13
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.29243
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr29243-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>Based on its cytologic features, and its co‐occurrence with atypical hyperplasia and breast cancer, flat epithelial atypia (FEA) has been proposed as a precursor lesion on the pathway to the development of breast cancer. It is often referred to as an "atypical" or high‐risk lesion. However, to the authors' knowledge, the long‐term risk of breast cancer in women with FEA is undefined.</p> </sec> <sec id="cncr29243-sec-0002" sec-type="section"> <title>METHODS</title> <p>Specimens with FEA were identified among excisional breast biopsies in the Mayo Clinic Benign Breast Disease Cohort, which includes 11, 591 women who had benign biopsy findings at the Mayo Clinic in Rochester, Minnesota between 1967 and 2001. Breast cancer risk among subsets of patients with FEA and nonproliferative, proliferative, and atypical hyperplasia (AH) was assessed using standardized incidence ratios (SIRs) compared with the Iowa Surveillance, Epidemiology, and End Results registry.</p> </sec> <sec id="cncr29243-sec-0003" sec-type="section"> <title>RESULTS</title> <p>FEA was identified in 282 women (2.4%); 130 had associated AH (46%) and 152 (54%) were classified as having proliferative disease without atypia (PDWA). With median follow‐up of 16.8 years, the SIR for breast cancer in patients with AH plus FEA was 4.74 (95% confidence interval [95% CI], 3.17‐6.81) versus 4.23 (95% CI, 3.44‐5.13) for those with AH without FEA (<italic>P</italic> = .59). The SIR for patients with PDWA plus FEA was 2.04 (95% CI, 1.23‐3.19) versus 1.90 (95% CI, 1.72‐2.09) for patients with PDWA without FEA (<italic>P</italic> = .76).</p> </sec> <sec id="cncr29243-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>FEA is an uncommon finding in women with benign breast disease. FEA does not appear to convey an independent risk of breast cancer beyond that of the associated PDWA or AH. <bold><italic>Cancer</italic> 2015;121:1548–1555</bold>. © <italic>2015 American Cancer Society</italic>.</p> </sec> </abstract>